CCG reports

Implementing the Cancer Strategy: How can the third-sector make a first-class contribution?

The Cancer Campaigning has launched its new report, 'Implementing the Cancer Strategy: How can the third-sector make a first-class contribution?' (November 2016).

The report’s message is simple. The third-sector plays an important role in the shaping and delivering of cancer services in England, and there is more the sector could offer to support the implementation of the Cancer Strategy, if provided with the operating structures to do so.  The third-sector cannot be third in the queue, but part of an approach which utilises the respective strengths of the public, private and third-sector; integrating or exercising an independent role as dictated by what will do the most for the patients for whom the cancer community works tirelessly.

The report, which is based on an in-depth survey of CCG members, includes several case studies from members which taken together highlight the ongoing contribution of the third-sector and how its role must be supported and further cultivated by the NHS organisations and the Department of Health, whose impact can be strengthened by expertise.

As decision-making increasingly, and simultaneously, involves more national bodies and devolves to a local level, third-sector organisations who worked from top-to-bottom and those who have grown from the grassroots, are a resource that must be tapped by NHS England, the Cancer Transformation Board and the Independent National Cancer Advisory Group.

The near-60 strong membership of the CCG has significant institutional knowledge and expertise which should be recognised as a valuable commodity to be mined and harnessed to make a first-class contribution towards the Cancer Strategy implementation process.

The report concludes by identifying recommendations for ensuring that the contribution of the third-sector is optimised, noting the unique patient voice the sector has at its very heart.  It is vital that this authentic voice is not lost in the mechanics and many technicalities involved in the implementation of the Cancer Strategy.

You can download the report by clicking on the image below:

cover-image_ccg-third-sector-report_page_01

Cancer Campaigning Group launches new Toolkit, 'Cancer Data: Empowering You To Act'

The Cancer Campaigning Group has launched its 2016 Cancer Data Toolkit, 'Cancer Data: Empowering You To Act'.  The new Toolkit is designed to help Members of Parliament access local cancer data, better enabling them to assess the quality of cancer services.  The Toolkit provides information about where to find cancer data relating to the following areas:

  • Incidence
  • Prevalence
  • Mortality
  • Survival
  • Patient experience
  • Waiting Standards
  • Screening and vaccination
  • Modifiable risk factors
  • Innovation Scorecard

The Toolkit also includes a number of questions about how cancer services in a particular area are performing in comparison to the best services in England.  You can download the Toolkit by clicking on the image below:

Twitter Profile


 

Cancer Campaigning Group statement submitted to Cancer Drugs Fund consultation

The Cancer Campaigning Group has published a statement submitted to the consultation on proposed changes to the Cancer Drugs Fund operating model.  After consulting with members and incorporating their views and feedback, the Cancer Campaigning Group's statement was shared with NHS England and NICE ahead of the consultation's closing date of Thursday 11 February 2016. The statement can be read in full here.

____________________________________________________________

Cancer Data: Empowering You to Act

In 2015, the Cancer Campaigning Group produced Cancer data - Empowering you to act.  This toolkit has been designed to support Members of Parliament to access the cancer data that tells them about their local services, allowing them to scrutinise their performance and compare them to the national average.

As well as making it easy to find these data, we have suggested a number of ways that MPs can take action in both Parliament and in their local area.  Armed with the best data and suggested actions, we are aiming to put MPs in a position to improve outcomes and experiences for local cancer patients and their families.

The toolkit was welcomed by Jane Ellison MP, Parliamentary Under-Secretary of State for Public Health, who attended the launch event held in Parliament in June 2015:

JE CCG launch

____________________________________________________________

Cancer Campaigning Group statement ahead of the Spending Review

The Cancer Campaigning Group has published a statement ahead of the next Government Spending Review calling for the latest cancer strategy, Achieving world-class cancer outcomes: a strategy for England 2015-2020, to be fully funded and implemented.  The statement can be seen in full here and has also been shared with the Chancellor of the Exchequer, George Osborne MP.

____________________________________________________________

Cancer: Shifting Gears - Bringing England's Cancer Outcomes In Line With The Best in Europe

The Cancer Campaigning Group has launched Cancer: Shifting Gears - Bringing England's Cancer Outcomes In Line With The Best In Europe.  The report sets out that the 60 members of the Cancer Campaigning Group have an ambition for the Government,the charity and voluntary sector, industry, the NHS, public health and social care systems, and the research and academic community to deliver truly world-class cancer outcomes.  We should be among the best in Europe.

The report outlines six visions for the future of cancer services, and calls on political parties to implement three urgent priority recommendations, outlined in full below:

1)  Strategic plan and annual update:  The next Government should work with NHS England and Public Health England to introduce a five-year strategic plan for improving cancer outcomes so that they are among the best in Europe.  This must outline the long-term ambitions for cancer across the patient pathway, including benchmarks for success, and set out how the NHS, public health and social care systems will be supported, resourced, enabled and held accountable for achieving the best outcomes in Europe. The plan must be accompanied by an annual implementation update, assessing the progress made in the previous year and next steps to deliver the plan.

2) Data: The NHS must continue to improve the scope and scale of data collection, using data to drive further research into personalised services and underpin more informed commissioning that is responsive to patient need and innovation. This will underpin the development and delivery of evidence-based interventions and services, while measuring impact more effectively. A framework for maintaining and improving our data capabilities must be included within the five-year strategic plan.

3) Integrated Cancer Services: Commissioners and providers must be supported to design and deliver integrated cancer services that are coordinated and seamlessly built around the needs of a patient. Improving patient experience must be central to this. The national strategic plan should outline the responsibilities for integrated cancer services, including the role that regional and local organisations can play.

Jane Ellison MP, Parliamentary Under-Secretary of State for Public Health welcomed the publication of the report via this video:

We were delighted that Liz Kendall MP, Shadow Minister for Care and Older People, John Baron MP, Chair of the APPG on Cancer, and Baroness Brinton, Co-Chair of the Liberal Democrat Backbench Health Committee were able to join us for the report's launch.

_________________________________________________________________

Results from the CCG’s survey of patients, carers and families about experiences and priorities for cancer care

The CCG undertook a survey of cancer patients, carers and professionals between March and May 2014, to understand more about their experiences and priorities of care.  Thank you to all members who circulated the survey through your networks – we were delighted to receive over 700 responses.  The Steering Group is now considering how to incorporate the results of the survey  into the CCG’s report (which is currently being drafted) to assess the progress made in cancer care since 2000, and the future vision for cancer care in the NHS.  The results can be downloaded here: CCG - Patient and carer survey results FINAL.

_________________________________________________________________

CCG launches briefing on patients' access to cancer medicines

The Cancer Campaigning Group is pleased to launch its briefing on patients' access to cancer medicines.  The briefing is based on a survey of CCG members, which took place during the summer.  It focuses on two issues: how CCG members work with NICE and the new system of value assessments.

The survey found that:

  • Just under two thirds of members who responded to the survey (61%) had been involved in submitting evidence to a NICE technology assessment
  • However, half (51%) did not think that NICE had come to the right decisions through technology appraisals they have been involved in
  • 48% of respondents were not sure if they had confidence in the NICE process, while only a quarter were confident
  • Almost two thirds of respondents (62%) responded to the Government consultation on the original proposals for value-based pricing
  • However, two thirds of respondents (65%) reported not being able to attend any of the workshops on the detail of the process organised by NICE or the Department of Health
  • 69% of respondents said they planned to be involved in the new value assessments if there was an opportunity
  • Worryingly, no respondents believed the new system will improve access to medicines despite this being one of the stated aims of the proposals

The briefing makes a series of recommendations for NICE and the Department of Health including that they should consult publicly and widely on the proposals for the value assessment before they are implemented, and to make the process for engaging with charities and patient representatives clear.

The briefing, which can be found here, is the first in a series of documents the CCG plans to produce about access to different types of cancer treatment which will be available on the CCG website in due course.

_________________________________________________________________

CCG early diagnosis slides

The Cancer Campaigning Group has collected case studies from CCG members on their activities on early diagnosis, and a showcase containing these examples is now available.

This document details members’ activities, including who the early diagnosis project was aimed at and how long it has been running for.

Early diagnosis is an important part of improving outcomes for people with cancer and this document provides an opportunity to learn from CCG members’ expertise and engagement in promoting early diagnosis of cancer.

The document will be updated as more examples are shared and is here for you to download.

_________________________________________________________________

Cancer Campaigning Group’s position statement on value-based pricing

The CCG believes that all cancer patients should have access to the clinically effective medicines their clinicians recommend for them, from the point of diagnosis through to the end of life.  The CCG wants to see a system of drug pricing and assessment that makes this possible.  In order to build a system which works for patients it is essential that patients and patient groups are able to contribute to this development process as well as being part of the implementation of the policy.  The CCG therefore feels that it is important to set out the group’s position in relation to the introduction of value-based pricing (VBP).

This document is now available for you to download and sets out the CCG position on a number of key areas and asks specific questions which the Department of Health needs to answer to ensure that any policy change does not restrict access for cancer patients to the treatments their clinicians wish to prescribe. This position has been developed by the membership.

Key areas of discussion within the position statement include:

  • Improving access to medicines
  • The pace of change
  • The role of NICE and health technology assessments (HTA)
  • End of life criteria
  • Wider societal benefits
  • Therapeutic innovation
  • Uptake of new medicines
  • Impact on rarer cancers

The full position statement is available here.  For more information contact the CCG on ccg@mhpc.com.

_________________________________________________________________

New report from the Cancer Campaigning Group shows that integration is vital for new NHS

Patients’ experience of integrated care, a new report from the Cancer Campaigning Group (CCG) shows that cancer patients need better integrated care. The report highlights the need for improvements in integrated care for cancer patients and calls for greater assessment of the experience of patients and carers when developing solutions and improvements.

This report is based on a survey of people living with cancer, and their carers, which was developed to help the CCG understand what matters most to them in relation to integrated care. Drawing on the responses, Patients’ experience of integrated care provides a snapshot of patients’ and carers’ experiences of cancer care and includes recommendations for future action to improve integrated care.

The survey found that one in three respondents thought that they had experienced integrated care. The fact that some of these were very positive indicates that it is possible to provide an integrated pattern of care and that best practice exists in the NHS. However, the results of the survey also indicate that more could be done to improve the experience of cancer patients in the NHS.

The survey also highlighted five key areas where patients thought improvements could be made to deliver integrated care. These were:

  • Securing quicker referral from GPs to hospitals for testing and diagnosis
  • Ensuring patients find out the results of their tests as quickly as possible
  • Providing patients with access to a named clinical nurse specialist or other ‘key worker’ throughout the care pathway
  • Supporting patients to feel involved in key decisions about their treatment and care
  • Putting systems in place to make sure records and test results are available to all clinicians and staff involved in patients’ care

The full report is available here.

_________________________________________________________________

CCG publishes report supporting the critical role of cancer networks in improving patients’ care

The Cancer Campaigning Group (CCG) has today (28.02.12) published a new report, Developing excellence in cancer networks, which calls for the NHS Commissioning Board to establish cancer networks as Strategic Clinical Networks and recommends a series of quality markers for what cancer networks can achieve when they’re working at their very best.

This latest piece of research uncovers insights from senior network staff about how networks can help to improve patient experience and outcomes, as well as support commissioners and providers to deliver high-quality cancer services.  The CCG hopes that this will be a useful contribution to the ongoing Department of Health work considering the role and responsibilities of clinical networks in the future.

About the report

The CCG commissioned a research company, Frontline, to conduct a series of qualitative interviews with professionals working in and around networks.

In-depth interviews have helped us to:

  • draw a picture of how cancer networks currently ‘add-value’ in terms of the design and delivery of cancer services
  • understand what their priorities are for the next three years
  • develop a vision of what a ‘gold standard’ cancer network would look like in the new health system

The full report can be viewed here.  If you have any questions, or would like further information, then please email ccg@mhpc.com.

_____________________________________________

CCG publishes vision for future of cancer services

The CCG has published six documents setting out our vision for the future of cancer services.  The documents are available here:

We hope that these visions will help to inform the development of future cancer services.  If you have any questions, or would like further information, then please email ccg@mhpc.com.

______________________________________________________________________

GPs say they need specialist advice to effectively commission cancer services (May 2011)

The Cancer Campaigning Group's report Ensuring effective commissioning of cancer services – A survey of GPs found that four in five (82%) GPs believe that GP commissioners will need specialist support if they are to commission cancer services effectively. Most GPs (71%) believe they, as individuals, will require specialist advice to effectively commission cancer services. The findings come from research into GPs' views on specialist commissioning support, carried out by ComRes.

These findings suggest that the quality of care cancer patients get could be adversely affected by the Government’s health reforms if GPs cannot access the commissioning support they need. The CCG believes cancer networks are ideally placed to provide this support. The cancer community is therefore calling for continued funding for cancer networks until GP consortia are fully up and running, with a commitment from the NHS Commissioning Board to retain their expertise for the longer-term.

Cancer Campaigning Group Steering Group member, Mia Rosenblatt said:

“It is critical that during this period, when the Government is listening to what people want from a reformed NHS, the Prime Minister and Health Secretary examine these insights from GPs and work with the cancer community to ensure cancer services continue to improve and deliver better outcomes and experiences for patients.”

The full data tables are available here and the full briefing is available here.

For more information on this briefing or for further information on the work of the CCG, please email ccg@mhpc.com or telephone 020 3128 8108.

It is supported by 9 companies:

  • Amgen
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Lilly
  • Novartis
  • Pfizer
  • Roche
  • Shire